Nubeqa
| Nubeqa | |
|---|---|
| Term | Nubeqa |
| Short definition | NTRK gene fusion - mutation (change) that occurs when a piece of the chromosome that contains a gene called NTRK breaks off and joins a gene on another chromosome. NTRK gene fusions result in abnormal proteins called TRK fusion proteins that can cause cancer cells to grow. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Nubeqa - (pronounced) (NOO-beh-kuh) A drug used alone or with docetaxel to treat adults with certain types of prostate cancer. Nubeqa is used in patients whose cancer has spread to other parts of the body and is responding to treatment that lowers testosterone levels, or whose cancer has not spread to other parts of the body and is no longer responding to treatment that lowers testosterone levels lowers. It is also being studied in the treatment of other types of cancer. Nubeqa attaches to proteins called androgen receptors, found in some prostate cancer cells. These proteins bind to androgens (male hormones) and can cause cancer cells to grow. Nubeqa blocks these proteins and can prevent cancer cells from growing. It's a type of antiandrogen. Also called darolutamide
External links
- Medical encyclopedia article on Nubeqa
- Wikipedia's article - Nubeqa
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski